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RESUMEN
Se hacen reaccionar las 3-aril-1-piridin-3-ilprop-2-en-1-
onas 1a,b con 2-cianoetanotioamida (2), rindiendo los 
correspondientes 4-aril-6-tioxo-1,6-dihidro-2,3’-bipiridina-
5-carbonitrilos 6a,b. En el presente estudio, se investiga la 
potencialidad sintética de los compuestos 6a,b mediante 
sus reacciones con diversos compuestos que contienen 
hidrógenos activos 8a-g, con el propósito de sintetizar las 
4-aril-6-piridin-3-iltieno[2,3-b]piridin-3-aminas 10a-n vía 
los 6-(alquiltio)-4-aril-2,3’-bipiridina-5-carbonitrilos 9a-n. 
Se elucidan las estructuras de todos los nuevos compues-
tos heterocíclicos sintetizados mediante los datos de los 
espectros de IR, 1H NMR y masas, así como de los análisis 
elementales. Se investigan las actividades anti-Alzheimer 
y anti-cox2 de todos los nuevos compuestos heterocícli-
cos sintetizados.
Palabras clave: 2-Cianoetanotioamida, 3-aril-1-piridin-
3-ilprop-2-en-1-onas, 6-tioxo-1,6-dihidro-2,3’-bipiridina-
5-carbonitrilo, 6-piridin-3-iltien[2,3-b]piridin-3-aminas, 
6-(alquiltio)-4-aril-2,3’-bipiridina-5-carbonitrilos. 
SUMMARY
3-Aryl-1-pyridin-3-ylprop-2-en-1-ones 1a,b reacted with 
2-cyanoethanethioamide (2) to afford the corresponding 
4-aryl-6-thioxo-1,6-dihydro-2,3’-bipyridine-5-carbonitriles 
6a,b. The synthetic potentiality of compounds 6a,b was 
investigated in the present study via their reactions with 
several active-hydrogen containing compounds 8a-g aim-
ing to synthesize 4-aryl-6-pyridin-3-ylthieno[2,3-b]pyridin-
3-amines 10a-n via 6-(alkylthio)-4-aryl-2,3’-bipyridine-5-
carbonitriles 9a-n. The structures of all newly synthesized 
heterocyclic compounds were elucidated by considering 
the data of IR, 1H NMR, mass spectra as well as that of el-
emental analyses. Anti-Alzheimer and anti-cox2 activities 
for all newly synthesized heterocyclic compounds were 
investigated.
Key words: 2-Cyanoethanethioamide, 3-aryl-1-pyridin-3-
ylprop-2-en-1-ones, 6-thioxo-1,6-dihydro-2,3’-bipyridine-
5-carbonitrile, 6-pyridin-3-ylthieno[2,3-b]pyridin-3-amines, 
6-(alkylthio)-4-aryl-2,3’-bipyridine-5-carbonitriles.
RESUM
Es fa reaccionar les 3-aril-1-piridin-3-ilprop-2-en-1-ones 
1a,b amb 2-cianoetantioamida (2), rendint els correspo-
nents 4-aril-6-tioxo-1,6-dihidro-2,3’-bipiridin-5-carbonitrils 
6a,b. En el present estudi, s’investiga la potencialitat sin-
tètica dels compostos 6a,b mitjançant les seves reaccions 
amb diversos compostos que contenen hidrògens actius 
8a-g, amb el propòsit de sintetitzar les 4-aril-6-piridin-
3-iltien[2,3-b]piridin-3-amines 10a-n via els 6-(alquiltio)-
4-aril-2,3’-bipiridina-5-carbonitrils 9a-n. S’eluciden les 
estructures de tots els nous compostos heterocíclics sin-
tetitzats mitjançant les dades dels espectres d’IR, 1H NMR 
i masses, així com dels anàlisis elementals. S’investiguen 
les activitats anti-Alzheimer i anti-cox2 de tots els nous 
compostos heterocíclics sintetitzats.
Mots clau: 2-Cianoetantioamida, 3-aril-1-piridin-3-ilprop-
2-en-1-ones, 6-tioxo-1,6-dihidro-2,3’-bipiridina-5-carbo-
nitril, 6-piridin-3-iltieno[2,3-b]piridin-3-amines, 6-(alquiltio)-
4-aril-2,3’-bipiridina-5-carbonitrils.
INTRODUCTION 
In conjunction to our previous recent work1-19  and aiming 
to investigate and evaluate the biological activities of the 
newly synthesized heterocyclic compounds we interested 
here to use 3-Aryl-1-pyridin-3-ylprop-2-en-1-ones as key 
compounds to synthesize 2,3’-bipyridine-5-carbonitriles 
required for several chemical transformations as well as 
our medicinal chemistry programs.
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RESULTS AND DISCUSSION
3-Phenyl-1-pyridin-3-ylprop-2-en-1-one20 (1a) reacted 
with 2-cyanoethane-thioamide (2) in absolute ethanol 
containing a catalytic amount of piperidine under re-
flux to afford a reaction product. Such reaction prod-
uct formed via a Michael addition of -CH2- in 2 on 
-CH=CH- of 1a to give the non-isolable products 3a, 
4a, 5a followed by cyclisation via dehydration and 
dehydrogenation to give 6a. The IR (cm-1) of this reac-
tion product showed the bands of NH (3169.7) and CN 
(2220) groups. Its mass spectrum gave m/z = 289.3 (100 
%) which corresponding to the molecular weight of the 
molecular formula C17H11N3S of the assigned structure 
as well as m/z = 256 (12.5 %) which corresponding to 
(M+ - SH) (cf. Scheme 1 and Exp. Part). 
In a similar manner, 3-(4-methoxyphenyl)-1-pyridin-3-
ylprop-2-en-1-one (1b) reacted with 2-cyanoethanethio-
amide (2) under the same above-mentioned experimental 
conditions to give the finally isolated 6b via the non-isol-
able intermediates 3b, 4b and 5b. Chemical structure 
of 6b elucidated by considering the data of IR, 1H NMR, 
mass spectra as well as that of elemental analyses (cf. 
Exp. Part). A further confirmation of 6a,b arose from their 
synthesis through other pathway via the reaction of each 
of 1a,b and malononitrile (7) in a dispersed sulfur, morpho-
line and ethanol under reflux 2 hours21. It important to refer 
here that 6a,b obtained by the two pathways are identical 
in all physical and chemical properties (cf. Exp. Part and 
Scheme 1).      
The synthetic potentiality of each of 6a,b investigated 
through electrophilic substitution reactions using sev-
eral electrophilc C-species. Thus, it has been found that 
1a reacted with ethyl chloroacetate (8a) in stirred meth-
anolic sodium methoxide at room temperature for 15 
minutes to give a reaction product. The IR (cm-1) of this 
reaction product showed the bands of CN (2220.1) and 
CO (1734.6) of the newly introduced COOEt group. Its 
1H NMR (δ ppm) spectrum revealed the signals of –SCH2-
,             -COOCH2CH3, -COOCH2CH3 protons and this 
confirm the good nucleophilicity of S in 6a that facilitate 
the electrophilic attack of 8a to afford 9a in very pure state 
and in a good yield. Furthermore, 9a structure elucidated 
through its cyclisation in ethanolic sodium ethoxide under 
reflux for 30 minutes to give a reaction product whose IR 
spectrum showed no bands of CN group and instead the 
bands of the newly formed NH2 group detected. Also, the 
1H NMR spectrum of this reaction product revealed no sig-
nals of –SCH2- protons while that of NH2 detected. Con-
sidering the data of both IR and 1H NMR we concluded 
that both –SCH2- and CN functional groups in 9a involved 
in the cyclisation step to give the finally isolated 10a. A 
further confirmation of 10a structure obtained through its 
preparation authentically via the reaction of 6a with 8a in 
ethanolic sodium ethoxide under reflux for 2 hours (cf. 
Exp. Part). Similarly, 6a reacted with each of 8c, e, g in 
stirred methanolic sodium methoxide at room temperature 
to give the corresponding 2-alkylthio derivatives 9c, e, g 
whose structures elucidated by considering the data of IR 
and elemental analyses (cf. Exp. Part). Also, 9c, e cyclized 
in ethanolic sodium ethoxide under reflux for 30 minutes 
and gave the corresponding thieno[2,3-b]pyridine deriva-
tives 10c, e respectively which obtained also via refluxing 
of 6a with each of 8c, e in ethanolic sodium ethoxide for 
2 hours. Unexpectedly, 9g didn’t undergoes cyclisation re-
action under varieties of experimental condition to give the 
corresponding thieno[2,3-b]pyridine derivative 10g.   
In contrast to the behavior of 6a towards each of 8a, c, 
e, g it has been found that 6a reacted with each 8b, d, 
f either in stirred methanolic sodium methoxide at room 
temperature or under reflux in ethanolic sodium ethoxide 
to give the corresponding thieno[2,3-b]pyridine derivatives 
10b, d, f respectively whose structures elucidated by con-
sidering the data of IR, 1H NMR, mass spectra as well as 
that of elemental analyses (cf. Exp. Part and Scheme 2). 
It important to report here that all trials aimed to isolate 
compounds 9b, d, f failed under varieties of experimental 
conditions. The structure of 10d confirmed further via its 
preparation through another road by reaction of 6a with 
or 3-chloropentan-2,4-dione (8d’) in methanolic sodium 
methoxide either under stirring at room temperature or re-
flux for 2 hours. The reaction seemed to be proceeded via 
the intermediates I and II through removal of acetic acid 
molecule to give 2-acetyl-3-amino-4-phenyl-6-(3-pyridyl)
thieno[2,3-b]pyridine (10d) (cf. equation 1).
In continuation to our effort for investigation the electro-
philic substitution reaction along the SH group in each of 
6a,b, compound 6b take as a key structure for that goal. 
Thus, it has been found that 6b reacted with each of 8a, 
b, c, e, f, g in stirred methanolic sodium methoxide for 15 
minutes to afford the corresponding 2-alkylthio derivatives 
9h, i, j, l, m, n. The structures of these reaction products 
elucidated by considering the data of their elemental anal-
yses, IR, 1H NMR (cf. Exp. Part). A further elucidation for 
these structures arose from their cyclisation in methanolic 
sodium methoxide under reflux for 30 minutes to give the 
corresponding thieno[2,3-b]pyridine derivatives 10h, i, j, l, Scheme 1
1. 278, 30748 (2003).
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m, n respectively. An authentic sample of each of 10h, i, 
j, l, m, n obtained via reflux mixture of 6b and each of 8a, 
b, c, e, f, g in ethanolic sodium ethoxide for 2 hours. In 
contrast to this behavior 6b reacted with 1-chloroacetone 
(8d) or 3-chloropentan-2,4-dione (8d’) either in methanolic 
sodium methoxide at room temperature for 15 minutes un-
der stirring or under reflux for 2 hours in ethanolic sodium 
ethoxide to give directly the corresponding thieno[2,3-b]
pyridine derivative 10k (cf. Figure 1). The structure of 10n 
confirmed further via its preparation authentically through 
the hydrolysis of 10h in ethanolic 10% KOH under reflux 
(cf. Exp. Part).
Biological Evaluation
Anti-Alzheimer activity 
For compounds 2 and 1a,b their relative potency individu-
ally is high enough while after their reactions to afford the 
corresponding bipyridine-5-carbonitriles 6a,b their relative 
potency decreased. Such compounds 6a,b reacted with 
several reagents to give compounds 9a, c, e, g, h, I, j, l, m, 
n which cyclized to give the corresponding thieno[2,3-b]
pyridines 10a-n. 
For series 9 the substituted pyridine derivatives have po-
tent activities where the compounds arranged according 
to descending order of activity 9g, 9e, 9a, 9c, 9i, 9l, 9m, 
9j, 9n, 9h, 6b, 6a (See Figure 1).
Its worth to mention that as the activity increases both 
the pharmacokinetics and pharmacodynamics properties 
greatly improved to be directed towards a good bioavail-
ability drug profiles (See Figures 2, 3). 
For series 10 where the pyridine is fused to another thio-
phene all the tested compounds showed moderate potent 
activities and the activity in descending order  is 10f, 10l, 
10b, 10i, 10k, 10j, 10n, 10m, 10h, 10d, 10c, 10a (see fig-
ures 4 and 5).
Generally the fusion of the thiophene ring onto the pyridine 
derivatives of compounds 9 result in compound 10 that of 
less activity than compounds 9 except that in the cases 
of 10h, i, l.
Structural Activity Relationship of anti-Alzheimer ac-
tivity
Generally for compounds 9 we note that the phenyl moiety 
provides the highest Anti-Alzheimer activity from phenyl-
p-methoxy. Thus, we can conclude that the p-methoxy 
group has no effect. The order of activity of relative poten-
cy for S-substition in all compounds 9 with phenyl moiety 
is: acid > ketone > ester > amide.
i.e. -S-CH
2COOH > -S-CH2COAr > -S-CH2COOEt > -S-
CH2CONH2
Anti-COx-2 activity
For series 9 the substituted pyridine derivatives have po-
tent activities where the compounds arranged according 
to descending order of activity 9h, 9n, 9e, 9i, 9m, 9a, (9c, 
6b), 9j, (9l, 9g) (See figure 6).
For series 10 where the pyridine is fused to another thio-
phene all the tested compounds showed more potent ac-
tivities and the activity in descending order is 10n, 10f, 10l, 
(10k & 10i), (10j & 10b), 10h, 10m. Generally the fusion of 
the thiophene ring onto the pyridine derivatives of com-
pounds 9 result in compounds 10 that of higher activity 
than compounds 9 (See   figure 7).
Structural Activity Relationship for anti-COx2 
Generally for compounds 9 the p-methoxyphenyl moiety 
provides the highest activity. The attaching of either a 
-COOEt or -COOH function to the SCH2 provides the high-
est activity while the attaching of either -CN or COC6H4-p-
Cl functions provide moderate activity. On the other hand, 
compounds 10 the p-methoxyphenyl moiety provides 
the highest activity. The attaching of either a -COOEt or 
-COOH function to the SCH2 provides the highest activity 
while the attaching of either -CN or -COC6H4-p-Cl func-
tions provide moderate activity. 
Acute toxicity of both compounds 9 and 10 illustrated by 
figures 8 and 9:
Y Ar 9 z Ar 10
COOEt C6H5 a COOEt C6H5 a
CONH2 C6H5 c CN C6H5 b
COPh C6H5 e CONH2 C6H5 c
COOH C6H5 g COMe C6H5 d
COOEt C6H4-4-OCH3 h COPh C6H5 e
CN C6H4-4-OCH3 i COPh-p-Cl C6H5 f
CONH2 C6H4-4-OCH3 j COOEt C6H4-4-OCH3 h
COPh C6H4-4-OCH3 l CN C6H4-4-OCH3 i
COPh-p-Cl C6H4-4-OCH3 m CONH2 C6H4-4-OCH3 j
COOH C6H4-4-OCH3 n COMe C6H4-4-OCH3 k
COPh C6H4-4-OCH3 l
COPh-p-Cl C6H4-4-OCH3 m
COOH C6H4-4-OCH3 n
R Y x 8
H COOEt Cl a
H CN Cl b
H CONH2 Cl c
H COMe Cl d
COMe COMe Cl d’
H COPh Br e
H COPh-p-Cl Br f
H COOH Cl g
Equation 1
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ExPERIMENTAL
All melting points were uncorrected. I.R. (KBr discs) spec-
tra were recorded on a Shimadzu FTIR-8201PC Spectro-
photometer. 1H-NMR spectra were recorded on a Varian 
Mercury 300 MHz., and a Varian Gemini 200 MHz. spec-
trometers using TMS as an internal standard and CDCl3, 
DMSO-d6, and (CD3)2CO as solvents. Chemical shifts were 
expressed as δ (ppm) units. Mass spectra were recorded 
on Shimadzu GCMS-QP1000EX using an inlet type at 70 
eV. The Micro analytical Center of Cairo University per-
formed the microanalyses.
Synthesis of 6a,b (General method):
Method A
A solution of each of 2 (2.6g; 2.6 mmole) and each of 1a,b 
(5.43g and 5.8g; 2.6 mmole) in absolute ethanol (30 mL) 
containing a catalytic amount of piperidine (0.4 mL) heated 
under reflux for 5 hours. The reaction mixture then evapo-
rated, cooled, triturated with ethanol. The products so 
formed collected by filtration, washed with cold ethanol, 
and then crystallized from the proper solvent to give the 
corresponding 6a,b, respectively.
Method B:
A mixture of dispersed sulfur (0.67 g; 1.9 mmole) and mor-
pholine (1.7mL; 1.9 mmole) in 50 mL of ethanol refluxed 
for 20 minutes. Add malononitrile (7) (1.3g; 1.9 mmole) 
and 1a,b (3.97g and 4.54g; 1.9 mmole) and the mixture re-
fluxed for 2 hours. The mixture cooled to ~ 20 °C, and 10% 
HCl added to reach pH 5-6. The precipitates so formed 
filtered off and washed with water and cooled ethanol then 
crystallized from dioxane to give the corresponding 6a,b 
respectively.       
4-Phenyl-6-thioxo-1,6-dihydro-2,3’-bipyridine-5-car-
bonitrile (6a): As orange crystals, yielded by 71%, m.p. 
240ºC, IR (ν cm-1):  3169.7 (NH), 3053 (aromatic-CH) and 
2220 (CN); MS: 289.3 (M+, 100% which corresponding to 
the molecular weight of the molecular formula C17H11N3S 
of the assigned structure), 287 (M+-2H, 84%); 256 (M+-
SH, 12.5%); 1h NMR (DMSO-D6) (δppm):  7.225-7.822(m, 
5H, Ph, protons), 8.195-9.012 (m, 5H, pyridine H,s) and 
14.10 (s, br, 1H, SH); Anal. for C17H11N3S (289) Calcd./
Found (%): C(70.56/70.60), H(3.83/3.90), N(14.52/14.58), 
S(11.08/11.16%).
4-(4-Methoxyphenyl)-6-thioxo-1,6-dihydro-2,3’-bipyri-
dine-5-carbonitrile (6b): as orange crystals, yielded by 
76%, m.p. 272 ºC; IR (ν cm−1): 3174 (NH), 3020 (aromat-
ic-CH) and 2216 (CN); MS: 319 (M+, 100% which corre-
sponding to the molecular weight of the molecular formula 
C18H13N3OS of the assigned structure), 318 (M
+-H, 30.6%), 
287 (M+-S, 4.6%); 1h NMR (DMSO-D6) (δppm): 3.855 (s, 
3H, OCH3), 7.117-7.841(m, 4H, Ar), 8.174-9.221 (m, 5H, 
pyridine H,s) and 14.2 (s, br, 1H, SH); Anal, for C18H13N3OS 
(319) Calcd./Found(%): C(67.69/67.72), H(4.10/4.14), 
N(13.16/13.19), and S (10.04/10.11%). 
Synthesis of 9a, c, e, g, h, i, j, l, m, n: (General Proce-
dure): A solution of each of 6a,b (0.29g and 0.32g 1mmole) 
and ethyl chloroacetate (8a), chloroacetonitrile (8b), 2-Chlo-
roacetamide (8c), 1-Chloroacetone (8d), 3-chloropentane-
2,4-dione (8d’), 2-bromo-1-phenyl-ethanone (8e), 2-bro-
mo-1-p-chlorophenylethanone (8f), Chloroacetic acid (8g), 
(0.122g, 0.076g, 0.093g, 0.092g, 0.134g, 0.198g, 0.233g 
and 0.094g 1 mmole) in sodium methoxide (prepared from 
0.14 g of sodium and methanol 25 mL) was stirring at room 
temperature for 15 minutes. The formed precipitate was 
collected by filtration, washed with water and crystallized 
from the proper solvent to give 9a, c, e, g, h, i, j, l, m, n 
respectively. 
Ethyl [(5-cyano-4-phenyl-2,3’-bipyridin-6-yl)thio]ac-
etate (9a): as a pale yellow crystals (87%), m.p = 196 °C; IR 
υ(cm-1): 3066.2 (C-H, aromatic), 2220.1 (CN), 1734.6 (ester 
CO); 1h NMR (DMSO-D6) (δppm): 1.166         (t, 3H, CH2CH3), 
2.498 (s, 2H, SCH2), 4.300(q, 2H, CH2CH3), 7.565-7.796(m, 
5H, phenyl H,s), 8.070-9.402(m, sH, pyridine H,s); Anal., 
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for C21H17N3O2S (375), Calcd./Found (%): C(67.18/67.23), 
H(4.56/4.61), N(11.19/11.23), S(8.54/8.61%).
2-[(5-Cyano-4-phenyl-2,3’-bipyridin-6-yl)thio]acet-
amide (9c): as a pale yellow crystals (84%), m.p = 265 °C; 
IR υ(cm-1): 3432.3, 3128.1 (NH2), 2215.3 (CN), 1684.4 
(CO amide); Anal., for C19H14N4OS (346), Calcd./Found 
(%): C(65.88/65.90%), H(4.07/4.11%), N(16.17/16.22%), 
S(9.26/9.30%).
6-[(2-Oxo-2-phenylethyl)thio]-4-phenyl-2,3’-bipyri-
dine-5-carbonitrile (9e): as orange  crystals (91%); m.p = 
210 °C; IR υ(cm-1): 3058.5 (C-H, aromatic), 2213.3 (CN), 
1690.6 (CO); Anal. for C25H17N3OS (407), Calcd./Found(%): 
C(73.69/73.72), H(4.21/4.26), N(10.31/10.40), S(7.87/7.90%).
[(5-cyano-4-phenyl-2,3’-bipyridin-6-yl)thio]acetic acid 
(9g): as orange crystals (80%); m.p = 300 °C; IR υ(cm-1): 
2927.5-3387 acid (OH), 3062.5 (CH, aromatic), 2214.5 
(CN); Anal. for C19H13N3O2S (347), Calcd./Found (%): 
C(65.69/65.73), H(3.77/3.85), N(12.10/1219), S(9.23/9.30).
Ethyl{[5-cyano-4-(4-methoxyphenyl)-2,3’-bipyridin-6-
yl]thio}acetate (9h):  as pale yellow crystals (80%); m.p = 
182°C; IR υ(cm-1): 3045 (C-H aromatic), 2214.6 (CN), 1736 
(ester CO). 1h NMR (DMSO-D6) (δppm): 2.501 (s, 2H, 
-SCH2-), 3.183-3.187 (overlapped, 3H, -CH2CH3), 3.865 
(s, 3H, OCH3), 4.285 (overlapped q, 2H, -CH2CH3), 7.792 
(m, 4H, Ar-H,s), 8.033-9.395 (m, 5H, pyridine); Anal. for 
C22H19N3O3S (405), Calcd./Found (%): C(65.17/65.21), 
H(4.72/4.80), N(10.36/10.43), S(7.91/8.00).
6-[(cyanomethyl)thio]-4-(4-methoxyphenyl)-2,3’-bipyri-
dine-5-carbonitrile (9i): as yellow crystals (84%); m.p = 185-
7 °C; IR υ(cm-1): 3051.4 (C-H aromatic), 2214.9 (CN); Anal. 
for C20H14N4OS (358) Calcd./Found (%): C(67.02/67.10), 
H(3.94/4.03), N(15.63/15.70), S(8.95/9.06).
2-{[5-cyano-4-(4-methoxyphenyl)-2,3’-bipyridin-6-
yl]thio}acetamide (9j) : as yellow crystals (84%); m.p = 
212 °C; IR υ(cm-1): 3391.7, 3204.4 (NH2), 3079 (C-H aro-
matic), 2216.9 (CN), 1666.7 (CO); Anal. for C20H16N4O2S 
(376) Calcd./Found (%): C(63.81/63.90), H(4.28/4.33), 
N(14.88/14.95), S(8.52/8.61).
6-[(2-oxo-2-phenylethyl)thio]-4-(4-methoxyphenyl)-
2,3’-bipyridine-5-carbonitrile (9l): as orange crystals 
(91%); m.p = 182 °C; IR υ(cm-1): 3046.3 (C-H aromatic), 
2213.2 (CN); Anal. for C26H19N3O2S (437), Calcd./Found (%): 
C(71.38/71.42), H(4.38/4.44), N(9.60/9.64), S(7.33/7.41). 
6-{ [2- (4-chlorophenyl ) -2-oxoethyl ] th io}-4- (4-
methoxyphenyl)-2,3’-bipyrid- ine-5-carbonitrile (9m): as 
yellow crystals (89%); m.p = 225 °C; IR υ(cm-1): 3064 (C-H ar-
omatic), 2206.6 (CN), 1697.4 (CO); Anal. for C26H18ClN3O2S 
(471), Calcd./Found (%): C(66.17/66.22), H(3.84/3.90), 
Cl(7.51/7.60), N(8.90/9.00), S(6.79/6.85).
{[5-cyano-4-(4-methoxyphenyl)-2,3’-bipyridin-6-yl]
thio}acetic acid (9n): as orange crystals (80%); map = 278 
°C; IR υ(cm-1): 3336.2-3529.4 (acidic OH), 3040.8 (C-H 
aromatic), 2209.8 (CN), 1653 (CO); 1h NMR (DMSO-D6) 
(δppm): 2.499 (s, 2H, -SCH2-), 3.855 (s, 3H, OCH3), 7.116- 
7.830 (m, 4H, Ar H,s), 8.169-9.217(m, 5H, pyridine H,s) and 
14.3 (s, br., 1H, COOH); Anal. for C20H15N3O3S (377) Calcd./
Found (%): C(63.65/63.70), H(4.01/4.10), N(11.13/11.20), 
S(8.50/8.58).
The synthesis of 10a-n: 
Method A:
 A solution of each of 9a, c, e, g, h, i, j, l, m, n (0.38g, 0.35g, 
0.41g, 0.35g, 0.41g, 0.36g, 0.38g, 0.44g, 0.47g, and 0.38g 
1mmole) in sodium ethoxide solution (prepared from 0.10 
g of sodium and 25 mL ethanol) heated under reflux for 30 
minutes. The solid that formed after cooling, collected by 
filtration, washed with water and ethanol then crystallized 
from the proper solvent to afford 10a-n respectively.
Method B:
 A solution of each of 6a,b (0.29g and 0.32g 1mmole) and 
ethyl-chloroacetate (8a), chloroacetonitrile (8b), 2-chloro-
acetamide (8c), 1-chloro-acetone (8d), 3-chloropentane-
2,4-dione (8d’), 2-bromo-1-phenylethanone (8e), 2-bromo-
1-(4-chlorophenyl)ethanone (8f) and chloroacetic acid (8g) 
(0.122g, 0.076g, 0.093g, 0.092g, 0.134g, 0.198g, 0.233g and 
0.094g 1 mmole) in sodium methoxide (prepared from 0.10g 
of sodium and 25 mL ethanol) heated under reflux for 2 hours. 
The solid products so formed after cooling, collected by filtra-
tion, washed with water and ethanol and dried then crystal-
lized from the proper solvent to afford 10a-n respectively.
Ethyl 3-amino-4-phenyl-6-pyridin-3-ylthieno[2,3-b]
pyridine-2-carboxylate (10a): as yellow crystals crystal-
lized from ethanol (90%); m.p = 180°C; IR υ(cm-1): 3478.5, 
3333.3 (NH2), 3057 (C-H aromatic),  1666.9 (CO);
 1h NMR 
(DMSO-D6) (δppm): 1.052 (t, 3H, CH2CH3), 3.443 (q, 2H, 
CH2CH3), 6.469 (s, br. 2H, NH2), 7.483-7.897 (m, 5H, phe-
nyl H,s) and 8.572-9.388 (m, 5H, pyridine H,s); Anal, for 
C21H17N3O2S (375), Calcd./Found (%): C(67.18/67.23), 
H(4.56/4.61), N(11.19/11.23), S (8.54/8.60).
3-Amino-4-phenyl-6-pyridin-3-ylthieno[2,3-b]pyridine-
2-carbonitrile (10b): as yellow crystals crystallized from 
ethanol (85%); m.p = 274°C; IR υ(cm-1): 3448.6, 3298.2, 
3180.7 (NH2), 3052.7(C-H aromatic), 2183.7 (CN); MS (m/z): 
328 ( M+, 100% which corresponding to the molecular weight 
of the molecular formula C19H12N4S of the assigned struc-
ture), 254 (M+-Pyridyl, 17%), 166 (Pyridine-CN, CN-C=C-NH2, 
5.3%), 140 (Pyridine, CN-C=C-NH2, 7.0%), 100 (Pyridine-CN, 
5.3%) and 66 (CN-C=C-NH2, 10.5%);  Anal. for C19H12N4S 
(328), Calcd./Found (%): C(69.49/69.52), H(3.68/3.72), 
N(17.06/17.12), S(9.76/9.82).
3-Amino-4-phenyl-6-pyridin-3-ylthieno[2,3-b]pyridine-
2-carboxamide (10c): as orange crystals crystallized from 
dioxane (80%); m.p = 225°C; IR υ(cm-1): 3475.7, 3433.1, 
3300.1, 3119.6 (NH2 and amidic NH2), 1645.7        (amidic 
CO); MS (m/z): 346 (M+, 100% which corresponding the 
molecular weight of the molecular formula C19H14N4OS of 
the assigned structure), 330 (M+-NH2, 7.5%), 329 (M
+-NH2-
H, 50.7%), 328 (M+-NH2-2H, 11.0%), 300 (M
+-CONH2-
2H, 84.9%), 256 (M+-PhCN-NH2, 35.6%), 228 (M
+-Ph-
CN-CONH2, 26.0%); Anal. for C19H14N4OS (346), Calcd./
Found (%): C(65.88/65.94), H(4.07/4.11), N(16.17/16.21), 
S(9.26/9.31%).
1-(3-Amino-4-phenyl-6-pyridin-3-ylthieno[2,3-b]pyri-
din-2-yl)ethanone (10d): as orange crystals crystallized 
from acetic acid (83%); m.p = 183 °C; IR υ(cm-1): 3485.8, 
3310.9 (NH2), 3054.2 (C-H aromatic), 1620.1 (CO); MS 
(m/z): 345 (M+, 100% which corresponding to the molecu-
lar weight of the molecular formula C20H15N3OS of the as-
signed structure), 344 (M+-H, 43.4%), 330 (M+-CH3, 56.2%), 
302 (M+-COCH3, 36.9%);
1h NMR (DMSO-D6) (δppm): 2.398 
(s, 3H, COCH3), 6.50 (s, br., 2H, NH2) 7.489-7.921 (m, 5H, 
phenyl H,s) and 8.579-9.396 (m, 5H, pyridine H,s); Anal. 
for C20H15N3OS (345), Calcd./Found (%): C(69.54/69.62), 
H(4.38/4.42), N(12.17/12.22), S(9.28/9.30).
(3-Amino-4-phenyl-6-pyridin-3-ylthieno[2,3-b]pyri-
din-2-yl)(phenyl)-methanone (10e): as orange crystals 
crystallized from dioxane (79%); m.p = 210°C; IR υ(cm-1): 
3469.5, 3382.3, 3305.3 (NH2), 3057 (C-H aromatic), 1678.7 
(CO); MS (m/z): 407 (M+, 84.3% which corresponding to 
the molecular weight of the molecular formula C25H17N3OS 
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of the assigned structure), 406 (M+-H, 100%), 302 (M+-
COPh, 28.2%), 105 (PhCO, 68.8%); Anal. for C25H17N3OS 
(407), Calcd./Found (%): C(73.69/73.75), H(4.21/428), 
N(10.31/10.38), S(7.87/7.94).
(3-amino-4-phenyl-6-pyridin-3-ylthieno[2,3-b]pyridin-2-
yl)(4-chlorophenyl)- ethanone (10f): as yellow crystals 
crystallized from dioxane (86%); m.p = 226 °C; IR υ(cm-
1): 3461.1, 3284.2 (NH2), 3053.5 (C-H aromatic), 1685.8 
(CO); MS (m/z): 442 (M+, 60.6% which corresponding to 
the molecular weight of the molecular formula C25H16Cl-
N3OS of the assigned structure), 443 (M+1, 29.9%), 440 
(M+-2H, 100%), 301 (M+-COC6H4-p-Cl, 10.3%); Anal. for 
C25H16ClN3OS (441.5), Calcd./Found (%): C(67.94/67.99), 
H(3.65/3.71), Cl(8.02/8.11), N(9.51/9.59), S(7.26/7.33).
Ethyl 3-amino-4-(4-methoxyphenyl)-6-pyridin-3-
ylthieno[2,3-b]pyrid-ine-2-carboxylate (10h): as yellow 
crystals crystallized from ethanol (88%); m.p = 219 °C; 
IR υ(cm-1): 3497.6, 3379.6 (NH2), 3062.1 (C-H aromatic), 
1665.1 (CO); MS (m/z): 405 (M+, 100% which correspond-
ing to the molecular weight of the molecular formula 
C22H19N3O3S of the assigned structure), 358 (M
+-C2H5, 
-H, 66.4%), 332 (M+-COOEt, 4.3%), 330 (M+-COOEt, 
-2H, 27.6%), 139 (-COC6H4Cl 31%);
1h NMR (DMSO-D6) 
(δppm): 1.284 (t, 3H, CH2CH3), 3.868 (s, 3H, OCH3), 4.274 
(q, 2H, CH2CH3), 5.908 (s, br. 2H, NH2), 7.141-7.484 (m, 
4H, Ar H,s) and 8.532-9.359 (m, 5H, pyridine H,s); Anal. 
for C22H19N3O3S (405) Calcd./Found (%): C(65.17/65.22), 
H(4.72/4.80), N(10.36/10.41), S(7.91/7.99).
3 - A m i n o - 4 - ( 4 - m e t h o x y p h e n y l ) - 6 - p y r i d i n - 3 -
ylthieno[2,3-b]pyridine-2-carbonitrile (10i): as orange 
crystals crystallized from Dioxane (90%); m.p = 210 °C; IR 
υ(cm-1): 3460.8, 3382.3, 3296.7 (NH2), 3065.1 (C-H aromat-
ic), 2188.1 (CN); MS (m/z): 358 (M+, 100% which corre-
sponding to the molecular weight of the molecular formula 
C20H14N4OS of the assigned structure), 357 (M
+-H, 34.6%), 
327 (M+-OCH3, 17.4%), 316 (M
+-CN-NH2, 5.3%), 313 (M
+-
NH2,-CN,-3H 19%); Anal. for C20H14N4OS (358), Calcd./
Found (%): C(67.02/6711), H(3.94/4.00), N(15.63/15.70), 
S(8.95/9.02).
3 - A m i n o - 4 - ( 4 - m e t h o x y p h e n y l ) - 6 - p y r i d i n - 3 -
ylthieno[2,3-b]pyridine-2-carboxamide (10j): as yellow 
crystals crystallized from acetic acid (81%); m.p = 268 °C; 
IR υ(cm-1): 3467, 3289 (NH2), 3407, 3126 (NH2), 1656 (CO),; 
MS (m/z): 376 (M+, 100% which corresponding to the mo-
lecular weight of the molecular formula C20H16N4O2S of the 
assigned structure), 360 (M+-NH2, 12%), 358 (M
+-NH2, -2H, 
80.8%), 332 (M+-CONH2, 5.2%), 330 (M
+-CONH2, -2H, 
44.3%); Anal. for C20H16N4O2S (376), Calcd./Found (%): 
C(63.81/63.90), H(4.28/4.33), N(14.88/1494), S(8.52/8.60).
1-[3-Amino-4-(4-methoxyphenyl)-6-pyridin-3-
ylthieno[2,3-b]pyridin-2-yl]ethanone (10k): as yellow 
crystals crystallized from acetic acid (86%); m.p = 233-6 °C; 
IR υ(cm-1): 3445, 3288.2 (NH2), 3033.4 (C-H aromatic),  1620 
(CO); MS (m/z): 375 (M+, 100% which corresponding to the 
molecular weight of the molecular formula C21H17N3O2S of 
the assigned structure), 374 (M+-H, 61.7%), 360 (M+-CH3 
40.5%), 332 (M+-COCH3 18.8%); Anal. for C21H17N3O2S 
(375), Calcd./Found (%): C(67.18/67.22), H(4.56/4.62), 
N(11.19/11.23), S(8.54/8.62).
( 3 -Amino-4- (4 -methoxypheny l ) -6 -pyr id in -3-
ylthieno[2,3-b]pyridin-2-yl)(phenyl)methanone (10l): as 
orange crystals crystallized from Dioxane (72%); m.p = 206 
°C; IR υ(cm-1): 3481.4, 3301.7 (NH2), 3045.7 (C-H aromat-
ic), 1656.2 (CO); MS (m/z): 437 (M+, 100% which corre-
sponding to the molecular weight of the molecular formula 
C26H19N3O2S of the assigned structure), 436 (M
+-H, 93%), 
105 (COPh, 20.9%); Anal. for C26H19N3O2S (437), Calcd./
Found (%): C(71.38//71.42), H(4.38/4.42), N(9.60/9.68), 
S(7.33/7.42).
( 3 -Amino-4- (4 -methoxypheny l ) -6 -pyr id in -3-
ylthieno[2,3-b]pyridin-2-yl)-(4-chlorophenyl)metha-
none (10m): as orange crystals crystallized from Dioxane 
(90%); m.p = 205 °C; IR υ(cm-1): 3479.6, 3306.8 (NH2), 
3040.3 (C-H aromatic), 1654 (CO); MS (m/z): 471 (M+, 
100% which corresponding to the molecular weight of the 
molecular formula C26H18ClN3O2S of the assigned struc-
ture), 473 (M+2, 37.0%), 472 (M+1, 50.3%), 470 (M+-H, 
99.2%), 469 (M+-2H, 11.7%), 139 (-COC6H4Cl, 31%); Anal. 
for C26H18ClN3O2S (471), Calcd./Found (%): C(66.17/66.22), 
H(3.84/3.90), Cl(7.51/7.60), N(8.90/8.98), S(6.79/6.82).
3 - A m i n o - 4 - ( 4 - m e t h o x y p h e n y l ) - 6 - p y r i d i n - 3 -
ylthieno[2,3-b]pyridine-2-carboxylic acid(10n) as orange 
crystals crystallized from acetic acid (71%), m.p = 320 °C; 
IR υ(cm-1): 3467.1 (NH2), 3230-3467 (acid OH); MS (m/z): 
332 (M+-COOH, 64.5%), 316 (M+-COOH-NH2, 43.5%), 
303 (M+-pyridyl, 9.7%), 289 (M+-CO2-CS, 64.5%);
1h NMR 
(DMSO-D6) (δppm): 3.854 (s, 3H, OCH3), 5.572 (s, br. 2H, 
NH2), 7.101-7.686 (m, 4H, Ar H
,s), 8.503-9325 (m, 5H, pyri-
dine H,s) and 14.3 (s, br., 1H, COOH); Anal. for C20H15N3O3S 
(377), Calcd./Found (%): C(63.65/63.71), H(4.01/4.11), 
N(11.13/11.19), S(8.50/8.59).
Materials and methods
1. Aβ42 and Aβ40 assay
Aβ42 and Aβ40 were measured in the culture medium of 
H4 cells, a human neuroglioma cell line expressing the 
double Swedish mutation (K595N/M596L) of human APP 
(APPsw). Cells were seeded onto 24-well plates (2×105 
cell well−1) and allowed to grow to confluence for 24h, in 
5% CO2/95% air in a humidified atmosphere. Increasing 
concentrations (from 3 to 300–400 µM) of the compounds 
were added to the cells overnight in a final volume of 0.5 
ml. R-flurbiprofen was used as positive control (3–1000 
µM). DMSO (1%) was used as negative control. At the end 
of the incubation, 100 µl of supernatants were removed 
and treated with a biotinylated mouse monoclonal anti-
body (4G8, Signet Laboratories Inc., Dedham, MA, USA), 
specifically recognizing the 17–24 amino acid region of 
Aβ and two rabbit polyclonal antibodies (C-term 42 and 
C-term 40, BioSource International, Camarillo, CA, USA), 
specifically recognizing the C-terminus of Aβ42 and Aβ40, 
respectively. Antigen-antibodies complexes were recog-
nized by TAG-donkey anti-rabbit IgG (Jackson Immuno 
Research Laboratories, Soham, UK). Streptavidin coated 
magnetic beads captured the complexes and the signals 
were read by an electrochemiluminescence instrument (Ori-
gen M8 Analyzer, BioVeris Corporation, Gaithersburg, MD, 
USA). The cytotoxicity potential of test compounds was 
assessed in the same cells of the Aβ assay (H4) with the 
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazol-ium bro-
mide (MTT) assay. MTT is a soluble pale yellow salt that is 
reduced by mitochondrial succinate dehydrogenase to form 
an insoluble dark blue formazan product to which the cell 
membrane is impermeable. The ability of cells to reduce MTT 
provides an indication of mitochondria integrity and activ-
ity and it may be interpreted as a measure of viability and/
or cell number. After medium removal for of Aβ 42 and Aβ 
40 determination, cells were incubated for 3 h with 500µl 
culture medium containing 0.5 mg ml−1 MTT, at 37 ºC, 5% 
CO2 and saturated humidity. After removal of the medium, 
500µl of 100% DMSO were added to each well. The amount 
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of formed formazan was determined reading the samples 
at 570 nm (background 630 nm) using a microplater reader 
(model 450, Bio-Rad, Hercules, CA, USA).
2. COX-1 and COX-2 assay
The inhibition of the cyclooxygenase activity was esti-
mated measuring PGE2 production from arachidonic acid 
according o a modified version of the method22. Recombi-
nant human prostaglandin H2 synthase-1 (PGHS-1) and -2 
(PGHS-2) were expressed in transfected Spodoptera fru-
giperda (Sf-9) cells (Invitrogen, San Diego,CA, USA). The 
microsomal fractions were prepared from the transfected 
cells and used to assay the enzymatic activities. Briefly, the 
enzymes (2g) reconstituted in a buffer (100mMTris–HCl, 
pH 8.0) containing 2mM phenol, were preincubated with 
vehicle (DMSO) or test compounds in DMSO (1%DMSO 
in the final assay) for 20 min at 22ºC. The reaction mixture 
was completed with 1M hematin. The reaction was initi-
ated adding arachidonic acid (4 and 2 µ for COX-1 and 
COX-2, respectively) and the mixture was incubated for 
5 min at 22ºC for COX-1 assay, or for 10 min at 25ºC for 
COX-2 assay. For control measurements, arachidonic acid 
was omitted from the reaction mixture. The reactions were 
stopped by the sequential addition of 1M HCl and 1M Tris-
HCl (pH 8.0), followed by cooling to  4ºC. The amount of 
PGE2 present in the reaction mixture was quantified using 
an enzyme-immunoassay.
3. Studies in Tg2576 transgenic mice
Young male and female transgenic mice (Tg2576) express-
ing the human APP gene with the Swedish double muta-
tion (K670N/M671L) under the transcriptional control of 
the hamster prion protein promoter23 were used for the in 
vivo studies. Male animals were housed singly in individual 
cages while female animals were placed in groups of 3–5 
animals per cage. The experiments were performed in ac-
cordance with EEC Guidelines (86/609/ECC) for the use of 
laboratory animals.
3.1. Study 1
Groups of mole mice 4-5 months, each group composed 
of twenty-one male mice of 4–5 months of age were given 
by oral gavage vehicle (Kool-Aid 7.5 ml kg−1) or a suspen-
sion of each individual compound (100 or 300 mg kg−1 
day−1 in Kool-Aid) once daily for 5 days. This vehicle was 
selected to replicate that reported with flurbiprofen in simi-
lar studies.24-26 On day 5, mice were given a final dose of 
100 or 300 mg kg−1 or vehicle and sacrificed 3 h later, as 
described below.
3.2 Study 2
Groups of female mice of 5-7 months of age, each group 
composed seventeen female mice of 5–7 months of age 
were given by oral gavage vehicle (Kool-Aid 7.5 ml kg−1) or 
a suspension of individual compound (100 or 300 mg kg−1 
day−1 in Kool-Aid) once daily for 4 days. On Day 4, mice 
were given a final dose of 100 or 300 mg kg−1 or vehicle 
and sacrificed 3 h later, as described below.
3.3 Study 3
Groups of male and female mice of 4–5 months, each 
group composed  of thirty-three male and female mice 
of 4–5 months were given vehicle or tested compounds 
or R-flurbiprofen-supplemented chow adlibitum for 4 
weeks. There were 11 animals in each treatment group. 
R-Flurbiprofen (Sigma, St. Louis, MO, USA) and the tested 
compounds were formulated into standard, color-coded, 
rodent diet by Charles River (Calco, Italy) at a final drug 
concentration of 375 ppm. The concentration of the drugs 
in the diet was the same as that used for flurbiprofen in 
previous studies.27-29 
Body weight and food consumption were monitored every 
3–4 days.
4. Plasma and brain Aβ measurements
Twenty-four hours before starting treatment, one blood 
sample was collected by means of retro-bulbar puncture 
for measurement of baseline plasma, Aβ40 and Aβ42 con-
centrations. On the last day of treatment, mice were sac-
rificed by decapitation. Blood samples were collected in 
EDTA-coated tubes and centrifuged at 800 rpm for 20 min. 
to separate plasma. Plasma samples were divided into 
two aliquots of approximately 100µl each and stored at 
−80 ºC until Aβ and drug assay. The brains were quickly 
removed and placed on an ice-cold plate. Cortex and hip-
pocampus were dissected and immediately frozen on dry 
ice and stored at −80ºC for Aβ assay. The remaining brain 
was immediately frozen on dry ice and stored at −80ºC 
for drug level measurements. Plasma was diluted 1:4 for 
Aβ42 and 1:20 for Aβ40. For measurement of Aβ, brain 
tissue samples were homogenized in 70% formic acid at 
1:10 (w/v). Homogenates were agitated at 4ºC for 3 h and 
then centrifuged at 15,000×g for 25 min at 4ºC. The super-
natants were collected and neutralized with 1M Tris, pH 11 
at 1:20 (w/v) dilution with 3 × protease inhibitor mixtures 
(Boehringer Mannheim, Mannheim, Germany). Levels of 
Aβ40 and Aβ42 in plasma and in brain homogenate super-
natants were measured with commercial ELISA kits (The 
Genetics Company, Zurich, Switzerland). The micro-titre 
plates were coated with capturing purified monoclonal an-
tibodies specifically recognizing the Cterminus of human 
Aβ40 (clone G2-10, reactive to amino acid residues 31–40, 
isotype IgG2b, kappa) or Aβ42 (clone G2-13, reactive to 
amino acid residues 33–42, isotype IgG1, kappa). As de-
tection antibody, a monoclonal biotin conjugated antibody 
recognizing the N-terminus of human Aβ (clone W0-2, re-
active to amino acid residues 4–10, isotype IgG2a, kappa) 
was used. The assay was linear in the range 25–500 pg 
ml−1 and the detection limit was 25 pgml−1.
5. Plasma and brain drug measurements
Drugs levels in plasma and in brain samples were mea-
sured by liquid chromatography as previously described.30 
Briefly, samples were prepared by adding 300µl acetonitrile 
and 40µl phosphoric acid 40% to 100µl plasma or brain 
homogenate and placing the mixture in a vortex for 5 s. 
Plasma and brain samples were then centrifuged at 14,000 
rpm for 5 min and the supernatants (15 and 50 µl, respec-
tively) were injected into the HPLC system. Equipment 
systems with fluorescence (Waters 474, Waters, Guyan-
court, France) or mass spectrometry (API 2000, Applied 
Biosystems, Foster City, CA, USA) detectors were used. 
The chromatographic conditions were adapted to each 
compound to obtain good peak separation and detec-
tion sensitivity. A mixture of ammonium formate (20 mM) 
buffer–acetonitrile–methanol was used as mobile phase 
for the fluorescence detector. For drugs the assay was lin-
ear in the range 20–4000 ng g−1 in the brain and 5–1000 
ng ml−1 in plasma with limits of quantitation of 20 ng g−1 
in the brain and 5 ng ml−1 in plasma. For drugs, he assay 
was linear between 400 and 20,000 ng g−1 in the brain and 
100–8500 ng ml−1 in plasma with limits of quantitation of 
400 ng g−1 in the brain and 100 ng ml−1 in plasma.
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